艾司西酞普兰联合rTMS对老年脑卒中后抑郁患者认知功能和负性情绪的影响

doi:10.3760/cma.j.issn.1007-1245.2024.21.003

摘要/Abstract

摘要：

目的　评估艾司西酞普兰联合重复经颅磁刺激（rTMS）在老年脑卒中后抑郁患者中的应用效果。方法　本研究为前瞻性、单中心、单盲、对照试验。选取榆林市星元医院在2021年1月至2023年12月收治的106例老年脑卒中后抑郁患者，通过随机数字表法分为两组，每组53例。对照组中，男29例、女24例，年龄（64.38±7.24）岁；观察组中，男27例、女26例，年龄（64.63±7.36）岁。对照组采用艾司西酞普兰治疗，观察组采用艾司西酞普兰联合rTMS治疗，4周为1个疗程，均治疗2个疗程。比较两组患者治疗前后单胺类神经递质水平、神经营养因子水平、脑血流状态［脑中动脉平均血流速度（Vm）、收缩期峰流速（Vs）、搏动指数（PI）］、脑白质结构变化，并通过蒙特利尔认知评估量表（MoCA）、汉密尔顿焦虑量表（HAMA）、汉密尔顿抑郁量表（HAMD）、卒中患者生活质量量表评估患者治疗前后的认知功能、负性情绪和生活质量。统计学分析采用t检验、χ²检验。结果　治疗后，观察组单胺类神经递质水平、神经营养因子水平高于对照组，脑白质损伤评分低于对照组；观察组患者Vm、Vs、PI分别为（57.88±6.95）cm/s、（96.67±8.32）cm/s、（0.68±0.19），对照组分别为（50.17±6.03）cm/s、（90.14±7.83）cm/s、（0.87±0.26）；观察组MoCA和生活质量评分分别为（24.18±3.01）分、（159.15±24.26）分，均高于对照组［（20.04±2.93）分、（130.52±20.18）分］，HAMA和HAMD评分分别为（12.26±2.09）分、（13.81±2.13）分，均低于对照组［（17.45±2.43）分、（18.69±2.34）分］；两组上述指标比较，差异均有统计学意义（均P<0.05）。结论　艾司西酞普兰联合rTMS治疗有助于提高老年脑卒中后抑郁患者的认知功能，并降低负性情绪。

关键词:

老年, 卒中后抑郁, 艾司西酞普兰, 重复经颅磁刺激, 认知功能, 负性情绪

Abstract:

Objective　To evaluate the effectiveness of escitalopram and repetitive transcranial magnetic stimulation (rTMS) for elderly patients with post-stroke depression. Methods　One hundred and six elderly patients with post-stroke depression treated at Xingyuan Hospital of Yulin from January 2021 to December 2023 were selected for the randomized controlled trial, and were divided into a control group and an observation group, with 53 cases in each group. In the control group, there were 29 males and 24 females who were (64.38±7.24) years old. In the observation group, there were 27 males and 26 females who were (64.63±7.36) years old. The control group took escitalopram, while the observation group took escitalopram and rTMS. Four weeks was one treatment cycle, and both groups were treated two cycles. The levels of monoamine neurotransmitters and neurotrophic factors, cerebral blood flow status [mean cerebral artery flow velocity (Vm), peak systolic flow velocity (Vs), pulsatility index (PI)], and changes in white matter structure were compared between the two groups before and after the treatment. Their cognitive functions, negative emotions, and quality of life were assessed using the Montreal Cognitive Assessment (MoCA), Hamilton Anxiety Scale (HAMA), Hamilton Depression Scale (HAMD), and Stroke-Specific Quality of Life Scale. t and χ² tests were used. Results　After the treatment, the levels of monoamine neurotransmitters and neurotrophic factors and score of white matter injury in the observation group were better than those in the control group; the Vm, Vs, and PI in the observation group were (57.88±6.95) cm/s, (96.67±8.32) cm/s, and (0.68±0.19), and those in the control group (50.17±6.03), (90.14±7.83) cm/s, and (0.87±0.26); the scores of MoCA, life quality, HAMA, and HAMD in the observation group were better than those in the control group [(24.18±3.01) vs. (20.04±2.93), (159.15±24.26) vs. (130.52±20.18), (12.26±2.09) vs. (17.45±2.43), and (13.81±2.13) vs. (18.69±2.34)]; there were statistical differences in the above indicators between the two groups (all P<0.05). Conclusion　Escitalopram combined with rTMS for elderly patients with post-stroke depression can improve their cognitive function and reduce their negative emotions.

Key words:

Elderly patients, Post-stroke depression, Escitalopram, Repetitive transcranial magnetic stimulation, Cognitive function, Negative emotions

宋海英刘艺高鹏举.

艾司西酞普兰联合rTMS对老年脑卒中后抑郁患者认知功能和负性情绪的影响 [J]. 国际医药卫生导报, 2024, 30(21): 3531-3536.

Song Haiying, Liu Yi, Gao Pengju.

Impact of escitalopram combined with repetitive transcranial magnetic stimulation on cognitive function and negative emotions in elderly patients with post-stroke depression [J]. International Medicine and Health Guidance News, 2024, 30(21): 3531-3536.

参考文献

[1] 祁杰,张磊,邓丽君,等. 卒中后抑郁患者脑白质纤维束改变及其与抑郁程度的相关性研究[J]. 中国全科医学,2022,25(9):1123-1129,1135. DOI:10.12114/j.issn.1007-9572. 2021.02.079.
[2] Wang Y, Zhou J, Chen X, et al. Effects of escitalopram therapy on effective connectivity among core brain networks in major depressive disorder[J]. J Affect Disord, 2024,350:39-48. DOI: 10.1016/j.jad.2024.01.115.
[3] Hart XM, Amann F, Brand J, et al. Low escitalopram concentrations in patients with depression predict treatment failure: a naturalistic retrospective study[J]. Pharmacopsychiatry, 2023,56(2):73-80. DOI: 10.1055/a-2039-2829.
[4] 任萌,单春雷. 重复性经颅磁刺激对脑卒中后抑郁的作用及其机制的研究进展[J]. 中华物理医学与康复杂志,2020,42(4):367-371. DOI:10.3760/cma.j.issn.0254-1424. 2020.04.019.
[5] Chen J, Xu P, Guo X, et al. Comparative analysis of the effects of escitalopram, pramipexole, and transcranial magnetic stimulation on depression in patients with parkinson disease: an open-label randomized controlled trial[J]. Clin Neuropharmacol, 2022,45(4):84-88. DOI: 10.1097/WNF.0000000000000507.
[6] 中华医学会神经病学分会,中华医学会神经病学分会脑血管病学组. 中国急性缺血性脑卒中诊治指南2018[J]. 中华神经科杂志,2018,51(9):666-682. DOI:10.3760/cma.j.issn.1006-7876.2018.09.004.
[7] 中华医学会精神病学分会. 中国精神障碍分类与诊断标准第三版(精神障碍分类)[J]. 中华精神科杂志,2001,34(3):184-188. DOI:10.3760/j:issn:1006-7884.2001.03.028.
[8] 谭双,李相华,刘春芹,等. 缺血性脑卒中后认知障碍患者血清肺腺癌转移相关转录因子-1及硫氧还蛋白互作蛋白水平的变化及意义[J]. 中国现代医学杂志,2022,32(13):26-31. DOI:10.3969/j.issn.1005-8982.2022.13.005.
[9] 赵昕,吴涵,王丹,等. 经颅交流电刺激治疗原发性失眠及伴发焦虑的疗效及安全性[J]. 河北医科大学学报,2023,44(8):900-904,928. DOI:10.3969/j.issn.1007-3205.2023.08.006.
[10] 卢越,刘丽,刘国华,等. 芪参还五胶囊配合穴位贴敷治疗脑梗死恢复期患者痰瘀互结证的疗效分析[J]. 中国现代医学杂志,2021,31(12):57-62. DOI:10.3969/j.issn.1005-8982. 2021.12.011.
[11] 唐甲凡,翟万庆,宋丽艳,等. 多种血清指标预测老年脑卒中后抑郁的临床价值[J]. 河北医科大学学报,2021,42(6):651-655,660. DOI:10.3969/j.issn.1007-3205.2021.06.007.
[12] Kacperczyk J, Perdyan A, Stompór M. Drug-resistant hyponatremia after escitalopram intake: a series of two case reports[J]. Ann Geriatr Med Res, 2021,25(3):217-221. DOI: 10.4235/agmr.21.0062.
[13] 庄超波. 艾司西酞普兰联合高频经颅磁刺激治疗脑卒中后抑郁患者的效果及其作用机制研究[J]. 中国医师杂志,2022,24(10):1586-1589. DOI:10.3760/cma.j.cn431274-20211213-01305.
[14] Wang J, Wang Y, Du X, et al. Potassium channel conductance is involved in phenylephrine-induced spontaneous firing of serotonergic neurons in the dorsal raphe nucleus[J]. Front Cell Neurosci, 2022,16:891912. DOI: 10.3389/fncel.2022.891912.
[15] Sun N, Cui WQ, Min XM, et al. A new perspective on hippocampal synaptic plasticity and post-stroke depression[J]. Eur J Neurosci, 2023,58(4):2961-2984. DOI: 10.1111/ejn.16093.
[16] Lin CC, Yang CP, Cheng PY, et al. Escitalopram reversibility of the impacts following chronic stress on central 5-HT profiles - Implications to depression and anxiety[J]. Behav Brain Res, 2023,453:114613. DOI: 10.1016/j.bbr.2023.114613.
[17] Nunez JJ, Liu YS, Cao B, et al. Response trajectories during escitalopram treatment of patients with major depressive disorder[J]. Psychiatry Res, 2023,327:115361. DOI: 10.1016/j.psychres.2023.115361.
[18] Kemps H, Gervois P, Brône B, et al. Non-invasive brain stimulation as therapeutic approach for ischemic stroke: Insights into the (sub)cellular mechanisms[J]. Pharmacol Ther, 2022,235:108160. DOI: 10.1016/j.pharmthera. 2022.108160.
[19] Marin Bosch B, Bringard A, Logrieco MG, et al. A single session of moderate intensity exercise influences memory, endocannabinoids and brain derived neurotrophic factor levels in men[J]. Sci Rep, 2021,11(1):14371. DOI: 10.1038/s41598-021-93813-5.
[20] Emon MPZ, Das R, Nishuty NL, et al. Reduced serum BDNF levels are associated with the increased risk for developing MDD: a case-control study with or without antidepressant therapy[J]. BMC Res Notes, 2020,13(1):83. DOI: 10.1186/s13104-020-04952-3.
[21] Wu D, Liu X, Gadhoumi K, et al. Causal relationship between neuronal activity and cerebral hemodynamics in patients with ischemic stroke[J]. J Neural Eng, 2020,17(2):026006. DOI: 10.1088/1741-2552/ab75af.
[22] Kawabata Y, Imazu SI, Matsumoto K, et al. rTMS therapy reduces hypofrontality in patients with depression as measured by fNIRS[J]. Front Psychiatry, 2022,13:814611. DOI: 10.3389/fpsyt.2022.814611.
[23] 随燕芳,宋振华,曾骥,等. 高频重复经颅磁刺激联合艾司西酞普兰对脑卒中后抑郁患者神经功能、抑郁状态及其血清炎症因子的影响[J]. 中华物理医学与康复杂志,2021,43(9):793-796. DOI:10.3760/cma.j.issn.0254-1424. 2021.09.005.